



Challenges and Opportunities in the Treatment of Patients With RAI-Refractory Differentiated Thyroid Cancer (DTC)

Chairpersons:

Marcia Brose, MD, PhD, and Martin Schlumberger, MD



Tuesday, 13 September 2011
13.00 – 14.00

Aula Duza (Main Hall)
Auditorium Maximum of the
Jagiellonian University
Kraków, Poland

Lunch will be provided at 12.30

Agenda

- 13.00 **Welcome and Introduction**
Alicja Hubalewska-Dydejczyk, MD, PhD
Jagiellonian University, Medical College
Kraków, Poland
- 13.05 **Challenges in Defining RAI-Refractory DTC and Review of the Current Treatment Algorithm**
Martin Schlumberger, MD
Institut Gustave Roussy
Villejuif, France
- 13.20 **Targeted Therapies in RAI-Refractory DTC: Rationale for Use and Clinical Development**
Marcia Brose, MD, PhD
University of Pennsylvania
Philadelphia, United States
- 13.40 **Multi-Disciplinary Perspectives in the Treatment of RAI-Refractory DTC: A Case-Study Approach**
Johannes Smit, MD, PhD
Leiden University Medical Center
Leiden, Netherlands
Marcia Brose, MD, PhD
Alicja Hubalewska-Dydejczyk, MD, PhD
Martin Schlumberger, MD
- 14.00 **Summary and Conclusion**
Marcia Brose, MD, PhD



Bayer HealthCare

Supported by Bayer HealthCare